

Authorship

Contribution: G.M. and R.H. designed the research, analyzed data, and wrote the paper; C.H., P.B., K.B., A.S., J.-M.S., H.G., and L.D. provided the data; and all authors reviewed and approved the final draft.

Conflict-of-interest disclosure: R.H., C.H., and P.B. have received consulting fees and/or honoraria from Bristol-Myers Squibb. The remaining authors declare no competing financial interests.

A complete list of the members of the Lymphoma Study Association appears in "Appendix."

Correspondence: Roch Houot, Department of Hematology, Centre Hospitalier Universitaire Rennes, 2 rue Henri Le Guilloux, 35033 Rennes Cedex 9, France; e-mail: roch.houot@chu-rennes.fr.

Appendix: study group members

The members of the Lymphoma Study Association are: Benoît Bateau, Cécile Borel, Nadine Boullanger, Olivier Casasnovas, Adrien Chauchet, Bénédicte Deau-Fischer, Alain Derlmer, Rémy Duléry, Marjan Ertault, Luc-Matthieu Fornecker, Georges Garnier, Thomas Gastinne, Stéphanie Guidez, Julien Lazarovici, Katell Le Dû, Fabien Lebras, Sophie Lefort, Elena Loppinet, Jean-Pierre Marolleau, Marie-Pierre Moles-Moreau, Lysiane Molina, Nadine Morineau, Franck Morschhauser, Emmanuelle Nicolas-Virelizier,

Frédéric Peyrade, Isabelle Roche-Lachaise, Anna Schmitt, Adrian Tempescul, Mohamed Touati, Olivier Tournihac, Elodie Gat, Laure Flament, and Florence Broussais.

REFERENCES

- Armand P, Engert A, Younes A, et al. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial. *J Clin Oncol*. 2018;36(14):1428-1439.
- Chen R, Zinzani PL, Fanale MA, et al; KEYNOTE-087. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. *J Clin Oncol*. 2017;35(19):2125-2132.
- Robert C, Ribas A, Hamid O, et al. Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma [published online ahead of print 28 December 2017]. *J Clin Oncol*. doi:10.1200/JCO.2017.75.6270
- Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. *J Clin Oncol*. 2007;25(5):579-586.
- Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. *J Clin Oncol*. 1999;17(4):1244-1253.

DOI 10.1182/blood-2018-03-841262

© 2018 by The American Society of Hematology

TO THE EDITOR:

A common *TCN1* loss-of-function variant is associated with lower vitamin B₁₂ concentration in African Americans

Yao Hu,¹ Laura M. Raffield,² Linda M. Polfus,³ Arden Moscatti,⁴ Girish Nadkarni,⁵ Michael H. Preuss,⁴ Xue Zhong,^{6,7} Qiang Wei,^{6,8} Stephen S. Rich,⁹ Yun Li,¹⁰⁻¹² James G. Wilson,¹³ Adolfo Correa,¹⁴ Ruth J. F. Loos,^{4,15,16} Bingshan Li,^{6,8} Paul L. Auer,¹⁷ Alex P. Reiner,^{1,18} and the NHLBI Trans-Omics for Precision Medicine Consortium

¹Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA; ²Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC; ³Center for Genetic Epidemiology, Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA; ⁴Charles Bronfman Institute for Personalized Medicine and ⁵Department of Nephrology, Icahn School of Medicine at Mount Sinai, New York, NY; ⁶Vanderbilt Genetics Institute, Nashville, TN; ⁷Department of Medicine, Vanderbilt University Medical Center, Nashville, TN; ⁸Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, TN; ⁹Center for Public Health Genomics, University of Virginia, Charlottesville, VA; ¹⁰Department of Genetics, ¹¹Department of Biostatistics, and ¹²Department of Computer Science, University of North Carolina at Chapel Hill, Chapel Hill, NC; ¹³Department of Physiology and Biophysics and ¹⁴Department of Pediatrics and Medicine, University of Mississippi Medical Center, Jackson, MS; ¹⁵Genetics of Obesity and Related Metabolic Traits Program and ¹⁶Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai, New York, NY; ¹⁷Zilber School of Public Health, University of Wisconsin-Milwaukee, Milwaukee, WI; and ¹⁸Department of Epidemiology, University of Washington, Seattle, WA

Vitamin B₁₂ (VB₁₂), or cobalamin, is a water-soluble vitamin. It serves as an enzyme cofactor in the 1-carbon metabolism pathway, which plays a key role in a wide range of biological processes, including red blood cell (RBC) formation, DNA synthesis, and myelination of the central nervous system.¹⁻³ VB₁₂ deficiency is clinically associated with megaloblastic anemia and neurodegenerative disorders and is also linked to cardiovascular diseases, which is thought to be mediated via hyperhomocysteinemia.^{1,3} Uptake of VB₁₂ from the diet in the gastrointestinal tract depends on intrinsic factor (encoded by *GIF*).^{3,4} VB₁₂ in blood is bound to haptocorrin (HC; encoded by *TCN1*) and transcobalamin (encoded by *TCN2*) and circulates as holohaptocorrin (holoHC) and holotranscobalamin, respectively.^{3,5,6}

Although VB₁₂ deficiency often results from poor gastrointestinal absorption,⁷ genetic factors also contribute to phenotypic variation. Previous genome-wide association studies (GWASs), primarily focusing on populations of European and Asian ancestry, have identified 13 loci (*FUT2*, *CUBN*, *TCN1*, *MUT*, *MS4A3*, *FUT6*, *PRELID2*, *CLYBL*, *CD320*, *TCN2*, *ABCD4*, *MMAA*, and *MMACHC*) associated with VB₁₂.⁸⁻¹⁵ GWASs in Chinese¹¹ and Indians¹⁴ identified VB₁₂-associated shared genetic variants across ancestry groups, as well as population-specific variants. VB₁₂ and holoHC concentrations are higher in blacks than in whites,¹⁶ yet no GWAS has examined the genetic determinants of VB₁₂ specifically in African Americans (AAs). In the current study, we used whole-genome sequencing (WGS) from the

Table 1. Association of *TCN1*-rs34530014 with *VB₁₂* concentration

Trait	Study	SNP	CHR:POS	N	EA/NEA	EAF	BETA (SE)	P*
VB ₁₂	JHS	rs34530014	11:59631467	1280	A/AC	0.036	-0.817 (0.104)	6.48 × 10 ⁻¹⁵
VB ₁₂	BioVU	rs11822978	11:59626896	725	T/C	0.034	-0.158 (0.038)	3.28 × 10 ⁻⁵
VB ₁₂	BioMe	rs11822978	11:59626896	3199	T/C	0.032	-0.272 (0.037)	2.76 × 10 ⁻¹³

CHR, chromosome; EA, effect allele; EAF, effect allele frequency; NEA, noneffect allele; POS, position; SE, standard error; SNP, single nucleotide polymorphism.

*Genome-wide significance was predefined as $P < 1.69 \times 10^{-9}$ or 0.05/29 665 030 variants tested.

National Heart, Lung, and Blood Institute (NHLBI) Trans-Omics for Precision Medicine (TOPMed) Program to assess genetic variants associated with *VB₁₂* in an unselected population-based sample of AAs from the Jackson Heart Study (JHS).¹⁷

The JHS is a population-based longitudinal study based in Jackson, Mississippi^{17,18}; additional information is reported in supplemental Methods (available on the *Blood* Web site). The JHS was approved by the Institutional Review Board of the




Figure 1. Locus-zoom plots. *TCN1*-rs34530014 (A) and *FUT2*-rs507766 (B). Genetic coordinates are displayed along the x-axis (Build 37/hg19), and genome-wide association significance level is plotted against the y-axis as $-\log_{10}(P$ value). The purple diamond indicates the top hit. LD is generated using JHS WGS data and is indicated by the color scale in relationship to the top hit, with red for strong LD ($r^2 > 0.8$) and navy blue for weak LD ($r^2 < 0.2$).

University of Mississippi Medical Center, and participants provided written informed consent. At the baseline examination, VB₁₂ was measured in plasma in a subset of 1851 JHS participants using a homogenous enzyme immunoassay system and Hitachi 911 equipment (Roche Diagnostics, Indianapolis, IN).¹⁹ A total of 3406 JHS participants underwent 30× coverage WGS through the TOPMed project at the Northwest Genome Center at the University of Washington, and genotype calling was performed by the Informatics Resource Center at the University of Michigan, as previously described.²⁰ After quality control (supplemental Methods), a total of 29 665 030 variants (minor allele frequency > 0.001) and 1280 participants (20.6–91.6 years of age, 65.5% female, VB₁₂ = 639.9 ± 289.3 pg/mL) were included in the discovery analysis (phs000964.v2.p1 for sequencing data and phs000286.v5.p1 for VB₁₂ data on the Database of Genotypes and Phenotypes; <https://www.ncbi.nlm.nih.gov/gap>).

Association of each single variant with rank-based inverse-normal-transformed VB₁₂ concentration was tested in JHS participants adjusted for age, sex, and the first 10 principal components (PCs) of genetic ancestry using a linear mixed model approach to account for familial relationships, as implemented in EPACTS 3.2.6 on the University of Michigan ENCORE server (<https://encore.sph.umich.edu>). Genome-wide significance was predefined as $P < 1.69 \times 10^{-9}$, or 0.05/29 665 030 variants tested; 33 variants across 2 genomic regions (*TCN1* and *FUT2*) reached genome-wide significance ($P < 1.69 \times 10^{-9}$) for VB₁₂ (supplemental Figure 1).

The index variant rs34530014 on chromosome 11 is a 1-bp deletion of *TCN1* (minor allele frequency = 0.036; $P = 6.48 \times 10^{-15}$; Table 1; Figure 1A) associated with lower VB₁₂. It is a loss-of-function (LoF) frameshift mutation (p.Val58Cysfs) prevalent only among African ancestry populations, originally reported in 2 Afro-Caribbean pedigrees with HC deficiency.²¹ Replication of the novel LoF variant *TCN1*-rs34530014 was performed using genomic data from 2 AA electronic medical record-linked biobanks: the Biobank of Vanderbilt University (BioVU)²² and BioMe of Mount Sinai²³ (supplemental Methods). Because *TCN1*-rs34530014 was not directly genotyped or imputed in BioVU or BioMe, we used its linkage disequilibrium (LD) proxy rs11822978 ($r^2 = 0.98$ in JHS) and confirmed its association with lower VB₁₂ in 3924 additional AAs from BioVU and BioMe (Table 1). *TCN1*-rs34530014 is distinct from other VB₁₂-associated *TCN1* variants (including 2 missense variants, rs34324219 and rs34528912) identified in Europeans and Indians.^{9,12–14} Of the *TCN1* variants previously associated with lower VB₁₂, only rs34324219 was nominally associated with lower VB₁₂ in the JHS ($P = .009$; supplemental Table 1). Together, these results demonstrate an ancestry-specific role for rs34530014 in lower VB₁₂ concentration in African ancestry populations and substantial allelic heterogeneity in the genetic architecture of VB₁₂ at the *TCN1* locus.

The identification of this naturally occurring LoF mutation prevalent in AAs allowed us to further investigate additional hematologic and clinical consequences of mild HC deficiency, beyond the association with lower VB₁₂ concentration. The association of rs34530014 with additional quantitative traits, including RBC indices and homocysteine, was assessed in the JHS and the Women's Health Initiative SNP Health Association Resource²⁴ (supplemental Methods). An elevated concentration of methylmalonate is a more sensitive and specific marker for

VB₁₂ deficiency^{1,3}; unfortunately, it was not available in our data sets. In addition, a phenome-wide association study (PheWAS) of *TCN1*-rs11822978 was performed in BioVU and BioMe. A total of 340 traits was scanned for association using logistic regression adjusted for age, sex, and the first 10 PCs, including diagnosis codes Vitamin Deficiency and Other Deficiency Anemia, none of these reached the Bonferroni-corrected threshold ($P > .006$, or 0.05/8 traits for RBC indices, supplemental Table 2; and $P > 1.47 \times 10^{-4}$, or 0.05/340 traits for PheWAS, supplemental Table 3).

In contrast to mutations of *TCN2*, which result in transcobalamin II deficiency (OMIM #275350) with severe clinical manifestations,²⁵ the clinical impact of HC deficiency is poorly defined. The distinct consequences of *TCN1* and *TCN2* mutations are consistent with the fact that holotranscobalamin is the bioactive form of VB₁₂ that is taken up by all tissues, whereas the biological role of holoHC is unclear.⁶ Despite the relatively large overall sample, the small number of homozygotes (4 in JHS) limited our ability to accurately assess the recessive effect of the *TCN1*-rs34530014 on VB₁₂ and related traits and disorders. Therefore, further investigation, including very large phenotypic data sets of African ancestry individuals, will be needed to draw firm conclusions about the clinical impact of HC deficiency.

The index single nucleotide polymorphism at the other genome-wide significant association peak in the JHS on chromosome 19 was rs507766 (located in the 3' untranslated region of *FUT2*; $P = 5.51 \times 10^{-11}$) (Figure 1B). This noncoding variant is in only moderate LD ($r^2 = 0.55$ in JHS) with the common secretor variant *FUT2*-rs601338 ($P = 1.49 \times 10^{-7}$ for association with VB₁₂ in JHS), which was previously identified in Europeans and Indians.^{8,9,14} Thus, we found evidence for 2 functional alleles involving *FUT2*: 1 with an additive genetic effect (rs507766) and 1 with a dominant effect (rs601338) on VB₁₂ (supplemental Table 4). We confirmed 4 previously identified loci (*MUT*, *MMACHC*, *FUT6*, and *CD320*; supplemental Table 1) at $P < .05$ with consistent association directions of effects.

We report a novel association between the African ancestry-specific LoF variant *TCN1*-rs34530014 and VB₁₂ concentration and an additional *FUT2* variant rs507766 associated with VB₁₂ specific to AAs, highlighting the ancestry heterogeneity of genetic factors that influence VB₁₂. Another population-specific VB₁₂-associated LoF variant, *CLYBL*-rs41281112 (p.Arg259Ter), is found in ~3% of apparently healthy non-African individuals (but is rare in Africans).¹¹ Further elucidation of the genetics and role of HC-bound VB₁₂ may lead to improved diagnosis and differentiation of true bioavailable VB₁₂ deficiency from total VB₁₂ deficiency.

Acknowledgments

The authors thank the staff and participants in the JHS. The contributions of the investigators of the NHLBI TOPMed Consortium (<https://www.nhlbiwgs.org/topmed-banner-authorship>) are gratefully acknowledged. The authors also gratefully acknowledge the

studies and participants who provided biological samples and data for TOPMed.

The JHS is supported and conducted in collaboration with Jackson State University (HHSN268201300049C and HHSN268201300050C), Tougaloo College (HHSN268201300048C), and University of Mississippi Medical Center (HHSN268201300046C and HHSN268201300047C) contracts from the National Institutes of Health (NIH) National Heart, Lung, and Blood Institute (NHLBI) and the National Institute for Minority Health and Health Disparities. The analysis was also funded by NIH NHLBI grants R01 HL129132 and R01 HL130733. WGS for the TOPMed program was supported by the NIH NHLBI. WGS for "NHLBI TOPMed: The Jackson Heart Study" (phs000964.v1.p1) was performed at the University of Washington Northwest Genomics Center (HHSN268201100037C). Centralized read mapping and genotype calling, along with variant quality metrics and filtering, were provided by the TOPMed Informatics Research Center (3R01HL-117626-02S1). Phenotype harmonization, data management, sample-identity quality control, and general study co-ordination were provided by the TOPMed Data Coordinating Center (3R01HL-120393-02S1). L.M.R. is supported by NIH NHLBI grant T32 HL129982. The BioVU data set used in the analyses described was obtained from the Vanderbilt University Medical Center, which was supported by institutional funding and by NIH National Center for Advancing Translational Science Clinical and Translational Science Awards grant ULTR000445. Genome-wide genotyping was funded by NIH National Institute of General Medical Sciences/OD grant RC2GM092618 and NIH National Human Genome Research Institute (NHGRI)/National Institute of General Medical Sciences grant U01HG004603. Analysis of BioVU data was partially funded by NHGRI grant U01HG009086, which supports the Vanderbilt Analysis Center for the Genome Sequencing Project. The Mount Sinai Institute for Personalized Medicine Biobank Program is supported by The Andrea and Charles Bronfman Philanthropies. Work in BioMe was also supported in part through the computational resources and staff expertise provided by Scientific Computing at the Icahn School of Medicine at Mount Sinai. R.J.F.L. is supported by NIH, National Institute of Diabetes and Digestive and Kidney Diseases grants R01DK110113, R01DK101855, and R01DK107786; and NIH, NHGRI grant U01HG007417.

The views expressed in this article are those of the authors and do not necessarily represent the views of the NHLBI, the NIH, or the US Department of Health and Human Services.

Authorship

Contribution: A.P.R. and P.L.A. were responsible for the study concept and design; J.G.W. and A.C. acquired the phenotypic and genotypic data in the JHS; A.P.R., P.L.A., Y.H., L.M.R., and L.M.P. performed the statistical analyses in the JHS and the Women's Health Initiative SNP Health Association Resource, the meta-analysis, and the PheWAS; A.M., G.N., M.H.P., and R.J.F.L. performed replication analysis in BioMe; X.Z., Q.W., and B.L. performed replication analysis in BioVU; Y.H. drafted the manuscript; and all authors contributed to the interpretation of the results and critical revision of the manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

A complete list of the members of the NHLBI Trans-Omics for Precision Medicine Consortium appears in the online appendix.

Correspondence: Alex P. Reiner, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle, WA 98109; e-mail: apreiner@u.washington.edu.

Footnote

The online version of this article contains a data supplement.

REFERENCES

1. Stabler SP. Vitamin B12 deficiency. *N Engl J Med*. 2013;368(21):2041-2042.

2. Stabler SP, Allen RH. Vitamin B12 deficiency as a worldwide problem. *Annu Rev Nutr*. 2004;24(1):299-326.
3. Green R. Vitamin B₁₂ deficiency from the perspective of a practicing hematologist. *Blood*. 2017;129(19):2603-2611.
4. Schjøsby H. Vitamin B12 absorption and malabsorption. *Gut*. 1989;30(12):1686-1691.
5. Nexø E, Hoffmann-Lücke E. Holotranscobalamin, a marker of vitamin B-12 status: analytical aspects and clinical utility. *Am J Clin Nutr*. 2011;94(1):359S-365S.
6. Gherasim C, Lofgren M, Banerjee R. Navigating the B(12) road: assimilation, delivery, and disorders of cobalamin. *J Biol Chem*. 2013;288(19):13186-13193.
7. Nielsen MJ, Rasmussen MR, Andersen CB, Nexø E, Moestrup SK. Vitamin B12 transport from food to the body's cells—a sophisticated, multistep pathway. *Nat Rev Gastroenterol Hepatol*. 2012;9(6):345-354.
8. Hazra A, Kraft P, Selhub J, et al. Common variants of FUT2 are associated with plasma vitamin B12 levels. *Nat Genet*. 2008;40(10):1160-1162.
9. Hazra A, Kraft P, Lazarus R, et al. Genome-wide significant predictors of metabolites in the one-carbon metabolism pathway. *Hum Mol Genet*. 2009;18(23):4677-4687.
10. Tanaka T, Scheet P, Giusti B, et al. Genome-wide association study of vitamin B6, vitamin B12, folate, and homocysteine blood concentrations. *Am J Hum Genet*. 2009;84(4):477-482.
11. Lin X, Lu D, Gao Y, et al. Genome-wide association study identifies novel loci associated with serum level of vitamin B12 in Chinese men. *Hum Mol Genet*. 2012;21(11):2610-2617.
12. Grarup N, Sulem P, Sandholt CH, et al. Genetic architecture of vitamin B12 and folate levels uncovered applying deeply sequenced large datasets. *PLoS Genet*. 2013;9(6):e1003530.
13. Keene KL, Chen WM, Chen F, et al. Genetic associations with plasma B12, B6, and folate levels in an ischemic stroke population from the Vitamin Intervention for Stroke Prevention (VISP) trial. *Front Public Health*. 2014;2:112.
14. Nongmaithem SS, Joglekar CV, Krishnaveni GV, et al. GWAS identifies population-specific new regulatory variants in FUT6 associated with plasma B12 concentrations in Indians. *Hum Mol Genet*. 2017;26(13):2589.
15. Velkova A, Diaz JEL, Pangilinan F, et al. The FUT2 secretor variant p.Trp154Ter influences serum vitamin B12 concentration via holo-haptocorrin, but not holo-transcobalamin, and is associated with haptocorrin glycosylation. *Hum Mol Genet*. 2017;26(24):4975-4988.
16. Carmel R, Brar S, Frouhar Z. Plasma total transcobalamin I. Ethnic/racial patterns and comparison with lactoferrin. *Am J Clin Pathol*. 2001;116(4):576-580.
17. Sempos CT, Bild DE, Manolio TA. Overview of the Jackson Heart Study: a study of cardiovascular diseases in African American men and women. *Am J Med Sci*. 1999;317(3):142-146.
18. Taylor HA, Jr., Wilson JG, Jones DW, et al. Toward resolution of cardiovascular health disparities in African Americans: design and methods of the Jackson Heart Study. *Ethn Dis*. 2005;15(4 Suppl. 6):S6-4-17.
19. Henry OR, Benghuzzi H, Taylor HA Jr, Tucci M, Butler K, Jones L. Suppression of homocysteine levels by vitamin B12 and folates: age and gender dependency in the Jackson Heart Study. *Am J Med Sci*. 2012;344(2):110-115.
20. Raffield LM, Zakai NA, Duan Q, et al; NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium, Hematology & Hemostasis TOPMed Working Group*. D-Dimer in African Americans: whole genome sequence analysis and relationship to cardiovascular disease risk in the Jackson Heart Study. *Arterioscler Thromb Vasc Biol*. 2017;37(11):2220-2227.
21. Carmel R, Parker J, Kelman Z. Genomic mutations associated with mild and severe deficiencies of transcobalamin I (haptocorrin) that cause mildly and severely low serum cobalamin levels. *Br J Haematol*. 2009;147(3):386-391.
22. Roden DM, Pulley JM, Basford MA, et al. Development of a large-scale de-identified DNA biobank to enable personalized medicine. *Clin Pharmacol Ther*. 2008;84(3):362-369.

23. Belbin GM, Odgis J, Sorokin EP, et al. Genetic identification of a common collagen disease in Puerto Ricans via identity-by-descent mapping in a health system. *eLife*. 2017;6:6.
24. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. *Control Clin Trials*. 1998;19(1):61-109.

25. Trakadis YJ, Alfares A, Bodamer OA, et al. Update on transcobalamin deficiency: clinical presentation, treatment and outcome. *J Inherit Metab Dis*. 2014;37(3):461-473.

DOI 10.1182/blood-2018-03-841023

© 2018 by The American Society of Hematology

TO THE EDITOR:

Plerixafor effectively mobilizes CD56^{bright} NK cells in blood, providing an allograft predicted to protect against GVHD

Peggy P. C. Wong,^{1,2,*} Amina Kariminia,^{3,*} David Jones,⁴ Connie J. Eaves,⁵⁻⁷ Ronan Foley,^{8,9} Sabine Ivison,³ Stephen Couban,¹⁰ and Kirk R. Schultz¹⁻³

¹Division of Pediatric Hematology/Oncology/Blood and Marrow Transplant, BC Children's Hospital, Vancouver, BC, Canada; ²Department of Pediatrics, University of British Columbia, Vancouver, BC, Canada; ³Michael Cuccione Childhood Cancer Research Program, BC Children's Hospital Research Institute, Vancouver, BC, Canada; ⁴Department of Medicine, Memorial University, St. Johns, NL, Canada; ⁵Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, BC, Canada; ⁶Department of Medicine and ⁷Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada; ⁸Hamilton Health Sciences Centre, Hamilton, ON, Canada; ⁹Department of Medicine, McMaster University, Hamilton, ON, Canada; and ¹⁰Department of Medicine, Dalhousie University, Halifax, NS, Canada

The recent *Blood* article by Schroeder et al demonstrates that plerixafor mobilizes a unique hematopoietic stem and progenitor cell (HSPC) product that is enriched in plasmacytoid dendritic cell (pDC) precursors (pre-pDCs).¹ This study further reports that enrichment of these cells in plerixafor-mobilized allografts is associated with lower cumulative incidence of acute graft-versus-host disease (aGVHD) and chronic graft-versus-host disease (cGVHD). In an earlier study, Waller et al reported a protective advantage against aGVHD of pDCs derived from bone marrow (BM) but not granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood (PB) graft.² Studies have shown that allogeneic transplantation with a BM allograft results in lower rates of aGVHD and cGVHD when compared with G-CSF-mobilized PB graft. In a commentary to the Schroeder study, Waller proposes that the relatively rapid onset of mobilization by plerixafor (hours vs days by G-CSF) generates a novel PB graft that immunologically and phenotypically resembles cells harvested from bone marrow.³ He hypothesizes that this unique allograft contains immune subsets, including pre-pDCs and pDCs, which favorably modulate alloreactivity post-transplantation thus resulting in lower GVHD rates.

Recently, the Canadian Blood and Marrow Transplant Group (CBMTG) conducted a phase 3 randomized trial and compared the impact of G-CSF-mobilized PB to BM. In this trial, G-CSF-treated BM donors had a significantly lower frequency of cGVHD,⁴ similar to that seen in the Schroeder study. A further comprehensive investigation of the donor graft composition found that the lower rate of cGVHD in G-BM correlated most closely with a higher proportion of CD56^{bright} regulatory NK cells (NK_{reg}) represented as the percentage of CD56^{bright} NK_{reg} cells.⁵ Additional evidence of the importance of this immune-regulatory population is our recent observation of a correlation of low numbers of CXCR3⁺CD56^{bright} NK_{reg} cells with the onset of cGVHD in adults.⁶ Based on these observations, we hypothesized that an alternate donor cell population, with a selective increase in NK_{reg} cells by plerixafor, may contribute to the lower rate of cGVHD seen in the recent Schroeder study.

To address this possible mechanism, we recruited 9 healthy adult human volunteers after full consent. This study was approved by the Dalhousie University and University of British Columbia (UBC) research ethical boards. All subjects were between 18 and 60 years of age and were enrolled at the Dalhousie University. All biological analyses were performed at the UBC-affiliated BC Children's Hospital Research Institute. Five subjects received 1 dose of plerixafor at 240 µg/kg per day subcutaneously and PB and BM samples were harvested prior to administration and at 4 and 24 hours after plerixafor administration. The subsequent 4 participants each received 4 daily doses of G-CSF at 5 µg/kg per day for 4 days, followed by a dose of plerixafor on day 5. To minimize the impact of circadian rhythm, PB and BM samples were collected between 9 AM and noon, prior to G-CSF administration, after G-CSF completion, and at 4 and 24 hours after plerixafor administration. We performed a focused analysis on CD56^{bright} NK_{reg} cells in these samples using multiparametric flow cytometry. Nucleated cells isolated from peripheral blood and bone marrow samples were stained with CD3, CD8, perforin, granzyme B, CD56 antibodies conjugated to fluorescein isothiocyanate, phycoerythrin, PB, Flow-Check 770 fluorospheres, and allophycocyanin, respectively. Stained cells were acquired by LSR II cytometer (BD) and the data were analyzed by FlowJo v10. The immunophenotype of NK_{reg} cells is CD3⁻, CD56^{bright}, perforin⁻ and granzyme-B⁻.

Plerixafor significantly mobilized nucleated cells to PB after 4 hours of treatment, whereas no significant difference was observed after 24 hours of treatment (Figure 1A). Furthermore, longer treatment time resulted in a significantly lower cell number indicating that plerixafor's action peaked at 4 hours after administration. The magnitude of mobilization observed 4 hours after plerixafor administration was similar to that seen in the previous phase II clinical study.⁷ Interestingly, plerixafor did not alter the nucleated cell number in the bone marrow (Figure 1A). Four daily injections of G-CSF followed by plerixafor administration significantly mobilized more nucleated cells to PB than either treatment alone (Figure 1B). However, the two agents mobilized similar number of nucleated cells to PB separately. Therefore, plerixafor mobilized nucleated cells to peripheral blood more rapidly than G-CSF.